Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 144

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 144
---
uted in January 2023). Pursuant to the Amendment, Trevally agreed to return 2,000 shares of the Company’s common stock, initially
issued to Trevally in January 2023 as advance consideration for agreeing to complete the synthesis of research materials for the Company.
Trevally returned the previously issued shares for no consideration on April 3, 2024. Trevally delivered the completed research materials
to the Company on July 1, 2024.

On July 12, 2024, the Company entered into an
At-the-Market Issuance Sales Agreement (the “ATM Agreement”) with WallachBeth Capital LLC as sales agent, to sell shares
of common stock having an aggregate offering price of up to $1,253,603 from time to time, through an “at the market offering”
program (the “ATM Offering”). The offer and sale of shares of common stock from the ATM Offering were made pursuant to the
Company’s shelf registration statement on Form S-3 and accompanying base prospectus (Registration Statement No. 333-280796) contained
therein which became effective on July 18, 2024. The prospectus supplement was subsequently amended four times to increase the maximum
aggregate offering price under the ATM Agreement. From July 19, 2024 to August 1, 2024, the Company sold a total of 135,568 shares in
the ATM Offering for gross proceeds of $1,994,583.

On July 22, 2024 and July 26, 2024, the Company
converted 1,291 and 1,032 shares of Series A Preferred Stock, respectively, held by Knight Therapeutics Inc. into 8,000 shares and 6,667
shares of common stock, respectively.

On October 1, 2024 and October 31, 2024, the
Company issued 41,311 shares and 45,800 shares of common stock, respectively upon the exercise of 41,311 and 45,800 September 2024 Pre-Funded
Warrants, respectively, resulting in aggregate cash proceeds to the Company of $436.

F-21

On December 10, 2024 and December 11, 2024, the
Company issued 50,800 shares and 56,600 shares of common stock, respectively, upon the exercise of 50,800 and 56,600 September
2024 Pre-Funded Warrants